LIB takes aim at cholesterol market with new PCSK9 option

LIB takes aim at cholesterol market with new PCSK9 option

[ad_1] Privately-held drug developer LIB Therapeutics has claimed FDA approval for a new once-monthly PCSK9 inhibitor – Lerochol – that can be used to reduce cholesterol levels. The injectable product has been approved alongside diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). According…

Read More